Drugs / ALBITIAZOLIUM
last change May 2017 re-read 2 minutes ago

ALBITIAZOLIUM

Small molecule

Developed for
malaria
Investigated by
Sanofi

Trials 2 · a red edge is where a trial was stopped

2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01445938 Oct 2011 → Jan 2012 malaria Sanofi Terminated No outcome recorded
Phase 2 NCT00739206 Aug 2008 → Jun 2009 malaria Sanofi Terminated No outcome recorded

Evidence & citations 11 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as ALBITIAZOLIUM ChEMBL registry synonym — accepted as the source's own label CHEMBL1183040
Known as ALBITIAZOLIUM BROMIDE ChEMBL registry synonym — accepted as the source's own label CHEMBL1183040
Known as Albitiazolium cation ChEMBL registry synonym — accepted as the source's own label CHEMBL1183040
Known as Albitiazolium ion ChEMBL registry synonym — accepted as the source's own label CHEMBL1183040
Known as Bromure d'albitiazolium ChEMBL registry synonym — accepted as the source's own label CHEMBL1183040
Known as Bromuro de albitiazolio ChEMBL registry synonym — accepted as the source's own label CHEMBL1183040
Known as SAR-97276 ChEMBL registry synonym — accepted as the source's own label CHEMBL1183040
Known as SAR97276A ClinicalTrials.gov intervention name — accepted as the source's own label NCT01445938
1

NCT00739206

Modality Small molecule “the choline analogue SAR97276A is a novel chemical entity” PMID 28472957 May 2017
Route Intramuscular “given either intramuscularly (IM) (0.18 mg/kg) or intravenously (IV) (0.14 mg/kg)” PMID 28472957 May 2017
Route Intravenous “given either intramuscularly (IM) (0.18 mg/kg) or intravenously (IV) (0.14 mg/kg)” PMID 28472957 May 2017